Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

What are the main environmental factors driving the development of the neurotoxic dinoflagellate Vulcanodinium rugosum in a Mediterranean ecosystem (Ingril lagoon, France)?

Abadie E, Chiantella C, Crottier A, Rhodes L, Masseret E, Berteaux T, Laabir M.

Harmful Algae. 2018 May;75:75-86. doi: 10.1016/j.hal.2018.03.012. Epub 2018 Apr 24.

PMID:
29778227
2.

Insights into the harmful algal flora in northwestern Mediterranean coastal lagoons revealed by pyrosequencing metabarcodes of the 28S rRNA gene.

Grzebyk D, Audic S, Lasserre B, Abadie E, de Vargas C, Bec B.

Harmful Algae. 2017 Sep;68:1-16. doi: 10.1016/j.hal.2017.06.003. Epub 2017 Jul 24.

PMID:
28962972
3.

Variation in Health Technology Assessment and Reimbursement Processes in Europe.

Akehurst RL, Abadie E, Renaudin N, Sarkozy F.

Value Health. 2017 Jan;20(1):67-76. doi: 10.1016/j.jval.2016.08.725. Epub 2016 Nov 3.

4.

Toxicity and Growth Assessments of Three Thermophilic Benthic Dinoflagellates (Ostreopsis cf. ovata, Prorocentrum lima and Coolia monotis) Developing in the Southern Mediterranean Basin.

Ben-Gharbia H, Yahia OK, Amzil Z, Chomérat N, Abadie E, Masseret E, Sibat M, Zmerli Triki H, Nouri H, Laabir M.

Toxins (Basel). 2016 Oct 15;8(10). pii: E297.

5.

Passive Sampling and High Resolution Mass Spectrometry for Chemical Profiling of French Coastal Areas with a Focus on Marine Biotoxins.

Zendong Z, Bertrand S, Herrenknecht C, Abadie E, Jauzein C, Lemée R, Gouriou J, Amzil Z, Hess P.

Environ Sci Technol. 2016 Aug 16;50(16):8522-9. doi: 10.1021/acs.est.6b02081. Epub 2016 Aug 4.

PMID:
27463836
6.

Toxin and Growth Responses of the Neurotoxic Dinoflagellate Vulcanodinium rugosum to Varying Temperature and Salinity.

Abadie E, Muguet A, Berteaux T, Chomérat N, Hess P, Roque D'OrbCastel E, Masseret E, Laabir M.

Toxins (Basel). 2016 May 5;8(5). pii: E136. doi: 10.3390/toxins8050136.

7.

Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease.

Smolen JS, Collaud Basset S, Boers M, Breedveld F, Edwards CJ, Kvien TK, Miossec P, Sokka-Isler T, van Vollenhoven RF, Abadie EC, Bruyère O, Cooper C, Mäkinen H, Thomas T, Tugwell P, Reginster JY; European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Ann Rheum Dis. 2016 Jul;75(7):1268-71. doi: 10.1136/annrheumdis-2016-209429. Epub 2016 Apr 1. Review.

8.

Exposure to the Paralytic Shellfish Toxin Producer Alexandrium catenella Increases the Susceptibility of the Oyster Crassostrea gigas to Pathogenic Vibrios.

Abi-Khalil C, Lopez-Joven C, Abadie E, Savar V, Amzil Z, Laabir M, Rolland JL.

Toxins (Basel). 2016 Jan 15;8(1). pii: E24. doi: 10.3390/toxins8010024.

9.

Effect of Nitrate, Ammonium and Urea on Growth and Pinnatoxin G Production of Vulcanodinium rugosum.

Abadie E, Kaci L, Berteaux T, Hess P, Sechet V, Masseret E, Rolland JL, Laabir M.

Mar Drugs. 2015 Sep 2;13(9):5642-56. doi: 10.3390/md13095642.

10.

β-N-methylamino-l-alanine (BMAA) and isomers: Distribution in different food web compartments of Thau lagoon, French Mediterranean Sea.

Réveillon D, Abadie E, Séchet V, Masseret E, Hess P, Amzil Z.

Mar Environ Res. 2015 Sep;110:8-18. doi: 10.1016/j.marenvres.2015.07.015. Epub 2015 Aug 1.

PMID:
26254582
11.

Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty.

Arden N, Richette P, Cooper C, Bruyère O, Abadie E, Branco J, Brandi ML, Berenbaum F, Clerc C, Dennison E, Devogelaer JP, Hochberg M, D'Hooghe P, Herrero-Beaumont G, Kanis JA, Laslop A, Leblanc V, Maggi S, Mautone G, Pelletier JP, Petit-Dop F, Reiter-Niesert S, Rizzoli R, Rovati L, Tajana Messi E, Tsouderos Y, Martel-Pelletier J, Reginster JY.

Drugs Aging. 2015 Jul;32(7):525-35. doi: 10.1007/s40266-015-0276-7. Review.

12.

Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis.

Reginster JY, Cooper C, Hochberg M, Pelletier JP, Rizzoli R, Kanis J, Abadie E, Maheu E, Brandi ML, Devogelaer JP, Branco J, Herrero-Beaumont G, D'Hooghe P, Bruyère O.

Curr Med Res Opin. 2015 May;31(5):1041-5. doi: 10.1185/03007995.2015.1027183. Epub 2015 Mar 24.

PMID:
25753599
13.

Beta-N-methylamino-L-alanine: LC-MS/MS optimization, screening of cyanobacterial strains and occurrence in shellfish from Thau, a French Mediterranean lagoon.

Réveillon D, Abadie E, Séchet V, Brient L, Savar V, Bardouil M, Hess P, Amzil Z.

Mar Drugs. 2014 Nov 17;12(11):5441-67. doi: 10.3390/md12115441.

14.

A feedback mechanism to control apoptosis occurs in the digestive gland of the oyster crassostrea gigas exposed to the paralytic shellfish toxins producer Alexandrium catenella.

Rolland JL, Medhioub W, Vergnes A, Abi-Khalil C, Savar V, Abadie E, Masseret E, Amzil Z, Laabir M.

Mar Drugs. 2014 Sep 25;12(9):5035-54. doi: 10.3390/md12095035.

15.

Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme.

Delzor A, Couratier P, Boumédiène F, Nicol M, Druet-Cabanac M, Paraf F, Méjean A, Ploux O, Leleu JP, Brient L, Lengronne M, Pichon V, Combès A, El Abdellaoui S, Bonneterre V, Lagrange E, Besson G, Bicout DJ, Boutonnat J, Camu W, Pageot N, Juntas-Morales R, Rigau V, Masseret E, Abadie E, Preux PM, Marin B.

BMJ Open. 2014 Sep 1;4(8):e005528. doi: 10.1136/bmjopen-2014-005528.

16.

Isolation of 12 microsatellite markers following a pyrosequencing procedure and cross-priming in two invasive cryptic species, Alexandrium catenella (group IV) and A. tamarense (group III) (Dinophyceae).

Laporte M, Shao Z, Berrebi P, Laabir M, Abadie E, Faivre N, Rieuvilleneuve F, Masseret E.

Mar Pollut Bull. 2014 Jun 15;83(1):302-5. doi: 10.1016/j.marpolbul.2014.04.017. Epub 2014 May 10.

PMID:
24820642
17.

Extended evaluation of polymeric and lipophilic sorbents for passive sampling of marine toxins.

Zendong Z, Herrenknecht C, Abadie E, Brissard C, Tixier C, Mondeguer F, Séchet V, Amzil Z, Hess P.

Toxicon. 2014 Dec;91:57-68. doi: 10.1016/j.toxicon.2014.03.010. Epub 2014 Apr 5.

PMID:
24709758
18.

A comparative analysis of Alexandrium catenella/tamarense blooms in Annaba Bay (Algeria) and Thau lagoon (France); phosphorus limitation as a trigger.

Hadjadji I, Frehi H, Ayada L, Abadie E, Collos Y.

C R Biol. 2014 Feb;337(2):117-22. doi: 10.1016/j.crvi.2013.11.006. Epub 2014 Feb 4.

PMID:
24581806
19.

Dietary BMAA exposure in an amyotrophic lateral sclerosis cluster from southern France.

Masseret E, Banack S, Boumédiène F, Abadie E, Brient L, Pernet F, Juntas-Morales R, Pageot N, Metcalf J, Cox P, Camu W; French Network on ALS Clusters Detection and Investigation.

PLoS One. 2013 Dec 13;8(12):e83406. doi: 10.1371/journal.pone.0083406. eCollection 2013.

20.

Pinnatoxin G is responsible for atypical toxicity in mussels (Mytilus galloprovincialis) and clams (Venerupis decussata) from Ingril, a French Mediterranean lagoon.

Hess P, Abadie E, Hervé F, Berteaux T, Séchet V, Aráoz R, Molgó J, Zakarian A, Sibat M, Rundberget T, Miles CO, Amzil Z.

Toxicon. 2013 Dec 1;75:16-26. doi: 10.1016/j.toxicon.2013.05.001. Epub 2013 May 30.

21.

Influence of environmental factors on the paralytic shellfish toxin content and profile of Alexandrium catenella (Dinophyceae) isolated from the Mediterranean Sea.

Laabir M, Collos Y, Masseret E, Grzebyk D, Abadie E, Savart V, Sibat M, Amzil Z.

Mar Drugs. 2013 May 15;11(5):1583-601. doi: 10.3390/md11051583.

22.

The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F.

Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24.

23.

More on influenza vaccine in young children.

Sancho A, Melchiorri D, Abadie E; Committee for Medicinal Products for Human Use, European Medicines Agency.

N Engl J Med. 2012 Jun 28;366(26):2528; author reply 2528-9. doi: 10.1056/NEJMc1205643. No abstract available.

24.

Open clinical trial data for all? A view from regulators.

Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G.

PLoS Med. 2012;9(4):e1001202. doi: 10.1371/journal.pmed.1001202. Epub 2012 Apr 10. No abstract available.

25.

The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Pean E, Demolis P, Moreau A, Hemmings RJ, O'Connor D, Brown D, Shepard T, Abadie E, Pignatti F.

Oncologist. 2012;17(4):543-9. doi: 10.1634/theoncologist.2011-0364. Epub 2012 Apr 3. Review.

26.

Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

Zannad F, Stough WG, Pocock SJ, Sleight P, Cushman WC, Cleland JG, McMurray JJ, Lonn E, Geller NL, Wedel H, Abadie E, Alonso-Garcia A, Pitt B.

Eur Heart J. 2012 May;33(9):1049-57. doi: 10.1093/eurheartj/ehr437. Epub 2012 Mar 15. Review.

PMID:
22422830
27.

Fifty years after thalidomide; what role for drug regulators?

Eichler HG, Abadie E, Baker M, Rasi G.

Br J Clin Pharmacol. 2012 Nov;74(5):731-3. doi: 10.1111/j.1365-2125.2012.04255.x. No abstract available.

28.

Adaptive licensing: taking the next step in the evolution of drug approval.

Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, Ferguson J, Garner S, Honig P, Hukkelhoven M, Lim JC, Lim R, Lumpkin MM, Neil G, O'Rourke B, Pezalla E, Shoda D, Seyfert-Margolis V, Sigal EV, Sobotka J, Tan D, Unger TF, Hirsch G.

Clin Pharmacol Ther. 2012 Mar;91(3):426-37. doi: 10.1038/clpt.2011.345. Epub 2012 Feb 15. Review.

PMID:
22336591
29.

The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

Hanaizi Z, van Zwieten-Boot B, Calvo G, Lopez AS, van Dartel M, Camarero J, Abadie E, Pignatti F.

Eur J Cancer. 2012 Jan;48(2):237-42. doi: 10.1016/j.ejca.2011.09.018. Epub 2011 Oct 24. Review.

PMID:
22030452
30.

The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

Nieto M, Borregaard J, Ersbøll J, ten Bosch GJ, van Zwieten-Boot B, Abadie E, Schellens JH, Pignatti F.

Clin Cancer Res. 2011 Nov 1;17(21):6608-14. doi: 10.1158/1078-0432.CCR-11-1734. Epub 2011 Oct 5. Review.

31.

The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP).

Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E, Pignatti F.

Oncologist. 2011;16(10):1451-7. doi: 10.1634/theoncologist.2011-0224. Epub 2011 Sep 30. Review.

32.

Regulators, payers, and prescribers: can we fill the gaps?

Pignatti F, Luria X, Abadie E, Eichler HG.

Lancet Oncol. 2011 Sep;12(10):930-1. doi: 10.1016/S1470-2045(11)70229-7. No abstract available.

PMID:
21958501
33.
34.

Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.

Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdóttir S, Rao R, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES).

Ann Rheum Dis. 2011 Oct;70(10):1713-8. doi: 10.1136/ard.2011.154252. Epub 2011 Jul 22. Review.

35.

Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, Rowland M, Schneider CK, Bloechl-Daum B.

Nat Rev Drug Discov. 2011 Jul 1;10(7):495-506. doi: 10.1038/nrd3501. Review.

PMID:
21720406
36.

The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.

Nieto M, Calvo G, Hudson I, Feldschreiber P, Brown D, Lee CC, Lay G, Valeri A, Abadie E, Thomas A, Pignatti F.

Haematologica. 2011 Sep;96(9):e33-40. doi: 10.3324/haematol.2011.048819. Epub 2011 Jun 28. Review.

37.

Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Durez P, Flamion B, Laslop A, Miossec P, Reiter S, Reginster JY; Task Force of the Group for the Respect of Ethics and Excellence in Science.

Rheumatology (Oxford). 2011 Oct;50(10):1732-6. doi: 10.1093/rheumatology/keq413. Epub 2011 Jan 17. No abstract available.

PMID:
21242246
39.

Rosiglitazone: a European regulatory perspective.

Blind E, Dunder K, de Graeff PA, Abadie E.

Diabetologia. 2011 Feb;54(2):213-8. doi: 10.1007/s00125-010-1992-5. Epub 2010 Dec 14. No abstract available.

PMID:
21153629
40.

Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.

Smolen JS, Boers M, Abadie EC, Breedveld FC, Emery P, Bardin T, Goel N, Ethgen DJ, Avouac BP, Dere WH, Durez P, Matucci-Cerinic M, Flamion B, Laslop A, Lekkerkerker FJ, Miossec P, Mitlak BH, Ormarsdóttir S, Paolozzi L, Rao R, Reiter S, Tsouderos Y, Reginster JY; Group for Respect of Ethics and Excellence in Science (GREES).

Curr Med Res Opin. 2011 Feb;27(2):315-25. doi: 10.1185/03007995.2010.542135. Epub 2010 Dec 9.

PMID:
21142618
41.

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium.

Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, Harpur E, Sonee M, Ennulat D, Holder D, Andrews-Cleavenger D, Gu YZ, Thompson KL, Goering PL, Vidal JM, Abadie E, Maciulaitis R, Jacobson-Kram D, Defelice AF, Hausner EA, Blank M, Thompson A, Harlow P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, Flamion B, Lima BS, Kasper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson-Gravatt D, Betton G, Davis MA, Akunda J, McDuffie JE, Suter L, Obert L, Guffroy M, Pinches M, Jayadev S, Blomme EA, Beushausen SA, Barlow VG, Collins N, Waring J, Honor D, Snook S, Lee J, Rossi P, Walker E, Mattes W.

Nat Biotechnol. 2010 May;28(5):455-62. doi: 10.1038/nbt.1625. Epub 2010 May 10.

PMID:
20458315
42.

Research at the interface of industry, academia and regulatory science.

Mattes WB, Walker EG, Abadie E, Sistare FD, Vonderscher J, Woodcock J, Woosley RL.

Nat Biotechnol. 2010 May;28(5):432-3. doi: 10.1038/nbt0510-432. No abstract available.

PMID:
20458309
43.

New drug approval success rate in Europe in 2009.

Eichler HG, Aronsson B, Abadie E, Salmonson T.

Nat Rev Drug Discov. 2010 May;9(5):355-6. doi: 10.1038/nrd3169. No abstract available.

PMID:
20431561
44.

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, König F, Pearson S.

Nat Rev Drug Discov. 2010 Apr;9(4):277-91. doi: 10.1038/nrd3079. Epub 2010 Feb 26. Review.

PMID:
20186141
46.

Safe drugs and the cost of good intentions.

Eichler HG, Abadie E, Raine JM, Salmonson T.

N Engl J Med. 2009 Apr 2;360(14):1378-80. doi: 10.1056/NEJMp0900092. No abstract available.

47.

A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants.

Melander H, Salmonson T, Abadie E, van Zwieten-Boot B.

Eur Neuropsychopharmacol. 2008 Sep;18(9):623-7. doi: 10.1016/j.euroneuro.2008.06.003. Epub 2008 Jul 14.

PMID:
18621509
48.

Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis.

Goldhahn J, Scheele WH, Mitlak BH, Abadie E, Aspenberg P, Augat P, Brandi ML, Burlet N, Chines A, Delmas PD, Dupin-Roger I, Ethgen D, Hanson B, Hartl F, Kanis JA, Kewalramani R, Laslop A, Marsh D, Ormarsdottir S, Rizzoli R, Santora A, Schmidmaier G, Wagener M, Reginster JY.

Bone. 2008 Aug;43(2):343-7. doi: 10.1016/j.bone.2008.04.017. Epub 2008 May 7. Review.

PMID:
18544475
49.

Report on the first detection of pectenotoxin-2, spirolide-a and their derivatives in French shellfish.

Amzil Z, Sibat M, Royer F, Masson N, Abadie E.

Mar Drugs. 2007 Nov 23;5(4):168-79.

50.

Genetic tests and genomic biomarkers: regulation, qualification and validation.

Novelli G, Ciccacci C, Borgiani P, Papaluca Amati M, Abadie E.

Clin Cases Miner Bone Metab. 2008 May;5(2):149-54.

Supplemental Content

Loading ...
Support Center